Erythropoietin Combined With L-carnitine Treatment Of Renal Anemia On Endothelin And Left Ventricular Remodeling

Objective Observed effects of maintenance hemodialysis patients with recombinant human erythropoietin (rhEPO) to renal anemia combined L-carnitine(LC), and function of Endothelin and left ventricular remodeling.Methods select 60 patients with uremia receiving maintenance hemodialysis who have been treaded more than 6 months(Hemodialysis 3 times/week, 4h/times); Hb <90 g/L, Hct <25%; No lack of iron, folic acid and vitamin B12; No resistant hypertension; No severe secondary hyperparathyroidism; No bleeding, infection, and malignant neoplasms affecting factors. 60 cases of hemodialysis patientswere randomly divided into treatment group and control group, each 30 cases. Two groups simultaneously on after hemodialysis were given rh-EPO 100～150U/kg by subcutaneous injection, Sub-3 subcutaneous. The patients in treatment group after dialysis intravenous were gave L-Carnitine 1.0g, totally 6 months. select 30 cases of non-uremic patients as the normal group.Detect the Blood pressure, hemoglobin (Hb), hematocrit (HCT), plasma endothelin (ET), left atrial diameter (LAD), left ventricular end systolic diameter (LVDs), left ventricular end diastolic diameter (LVDd).Results Hb and Hct in Treatment group and control group two groups patients were significantly higher than that before treat-ment,and the treatment group better than the group(P<0.05),the difference was statistically significant; ET:in Treatment group and control group two groups the difference was no significant(P<0.05); The two compared with the normal group was significantly different (P<0.05),it show that Urea patients have significantly higher plasma ET levels。After treatment, the ET levels of treatment groups were significantly decreased(P<0.05), ET levels in the control group were increased,There was a significant difference(P<0.05); After the treatment of patients with elevated diastolic blood pressure≥10mm Hg(1mmHg=0.133kPa), As blood pressure standard. In the treatment group, 2 cases of high blood pressure patients, accounting for 6.7%. In the control group, 9 cases of high blood pressure patients, accounting for 30%. There was significant difference (P<0.05); After 6 months, in treatment group,LAD,LVDs, LVDd was decreased, Compared with before treatment, the difference was statistically significant (P<0.05); Compared with the control group, the difference was statistically significant (P<0.05).Conclusion L-carnitine can significantly increase the efficacy what erythropoietin treated renal anemia,Reduced plasma endothelin levels,reduce the incidence of adverse reactions,Improve or inhibit the occurrence of ventricular remodeling,development, Prevent the occurrence of heart failure.